Alpha Tau Medical Ltd Asset Resilience Ratio
Alpha Tau Medical Ltd asset resilience ratio. Alpha Tau Medical Ltd (DRTS) has an Asset Resilience Ratio of 65.79% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See operational self-sufficiency of Alpha Tau Medical Ltd to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Alpha Tau Medical Ltd (2019–2024)
Asset resilience ratio of Alpha Tau Medical Ltd from 2019 to 2024. This chart shows how Alpha Tau Medical Ltd's Asset Resilience Ratio has changed over time. Read Alpha Tau Medical Ltd balance sheet liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Alpha Tau Medical Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see DRTS total asset value.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $68.88 Million | 65.79% |
| Total Liquid Assets | $68.88 Million | 65.79% |
Asset Resilience Insights
- Very High Liquidity: Alpha Tau Medical Ltd maintains exceptional liquid asset reserves at 65.79% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Alpha Tau Medical Ltd Industry Peers by Asset Resilience Ratio
Compare Alpha Tau Medical Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Hyloris Developmentsen Sa
BR:HYL |
Biotechnology | 1.36% |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
Oruka Therapeutics, Inc.
NASDAQ:ORKA |
Biotechnology | 53.11% |
|
Gempharmatech Co. Ltd. A
SHG:688046 |
Biotechnology | 23.95% |
|
Vor Biopharma Inc
NASDAQ:VOR |
Biotechnology | 74.48% |
|
Inventiva S.A
PA:IVA |
Biotechnology | 52.73% |
|
Sunmax Biotechnology Co Ltd
TWO:4728 |
Biotechnology | 10.53% |
|
Guangdong VTR Bio-Tech Co Ltd
SHE:300381 |
Biotechnology | 4.98% |
Alpha Tau Medical Ltd Asset Resilience Ratio by Year (2019–2024)
Alpha Tau Medical Ltd asset resilience ratio by year from 2019 to 2024. The table below shows the annual Asset Resilience Ratio data for Alpha Tau Medical Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 53.22% | $45.88 Million | $86.20 Million | -11.16pp |
| 2023-12-31 | 64.37% | $69.13 Million | $107.39 Million | -17.77pp |
| 2022-12-31 | 82.14% | $98.69 Million | $120.15 Million | +63.00pp |
| 2021-12-31 | 19.14% | $8.08 Million | $42.22 Million | -38.26pp |
| 2020-12-31 | 57.40% | $30.42 Million | $52.99 Million | -25.93pp |
| 2019-12-31 | 83.33% | $26.30 Million | $31.56 Million | -- |
About Alpha Tau Medical Ltd
Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer. Its Alpha-DaRT technology is in clinical trials for various forms comprising skin, oral, pancreatic, prostate, lung, liver, and breast cancers; and preclinical or pending cl… Read more